Ambrosia Biosciences Announces Nonclinical Data for Oral Small Molecule Programs

News related to:Ambrosia Biosciences · 1 min read
BOULDER, Colo., Nov. 15, 2026 /CourierPR/ -- Ambrosia Biosciences Inc. ("Ambrosia") has announced the nonclinical data profiles of two oral small molecule programs, AMB-895 and AMB-131, at The Obesity Society's Annual Meeting, ObesityWeek® 2026. These programs, designed to address obesity and related metabolic disorders, have shown promising results in preclinical models.
AMB-895, a novel oral small molecule GLP-1 receptor agonist intended for once-weekly dosing, demonstrated sustained target coverage greater than EC70 over one week, following a single 1 mg/kg oral dose in lean non-human primates (NHP). The compound also resulted in sustained weight loss and reduced food intake over 14 days of once-weekly oral dosing in a lean NHP model. Specifically, when dosed at 1 mg/kg, AMB-895 achieved an 8% mean weight loss from baseline at day 14.
AMB-131, a novel oral small molecule GIP receptor antagonist, demonstrated higher exposure and target coverage at 24 hours in both mouse and NHP models. Additionally, AMB-131 enhanced weight loss induced by semaglutide in a mouse model of diet-induced obesity.
The company's pipeline includes AMB-895, designed for once-weekly dosing, and AMB-702, for once-daily dosing. These programs, along with Ambrosia's GIP receptor antagonist and amylin agonist programs, form a comprehensive and differentiated pipeline aimed at pursuing both opportunities in the treatment of metabolic diseases.
Ambrosia Biosciences Inc. is a privately held drug discovery company developing next-generation oral small molecule therapies for obesity and other metabolic disorders. By integrating structurally-enabled drug design with in-house medicinal chemistry and biology capabilities, Ambrosia is advancing a complementary pipeline of differentiated therapies. The company aims to expand access to cardiometabolic therapies that improve the patient experience while reducing the cost and complexity of treatment.
These nonclinical data were shared as poster presentations at ObesityWeek® 2026, a significant event in the field of obesity research and treatment. The findings highlight the potential of Ambrosia's programs to offer innovative solutions for managing obesity and related metabolic conditions.